2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update

Save

EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).

2023 Rheumatology Year in Review

Save

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  

2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  

2023 Rheumatology Year in Review

Save

Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.

2023 In Memoriam

Save

In 2023, too many of our rheumatology colleagues passed away. Here is an incomplete list of our revered fellow practitioners, mentors, role-models, and researchers.

Florida Approves Import of Drugs from Canada

Save

Last Friday, the Food and Drug Administration (FDA) approved Florida’s plan to import certain prescription drugs directly from Canada.  Florida is the first time a state to undertake this pathway to save money.

New Year's Resolutions (1.5.2024)

Save

Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.

Best of 2023: ACR Guidelines for Interstitial Lung Disease in Patients with Rheumatic Conditions

Save

The American College of Rheumatology released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease

Save

The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published validated classification criteria for symptomatic CPPD disease.